Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLL-17 clofarabine combination chemotherapy study in infant ALL
jRCTs041190043Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year event-free survival rate. Started Jun 2019; status: active, not recruiting.
02
Drugs
clofarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041190043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190043.